P&G Pharma Keeps Low Profile In Reorganization; Squeezes In With Charmin
Procter & Gamble has ambitious plans for growing its health care business - but the role for its prescription drugs business is likely to remain decidedly low-key
You may also be interested in...
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
Procter & Gamble CEO-elect A.G. Lafley will inherit the task of settling the appropriate size for P&G's investment in the pharmaceutical business.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011